NEUROCRINE BIOSCIENCES INC Payments to Acquire Restricted Investments
NEUROCRINE BIOSCIENCES INC (NBIX) reported Payments to Acquire Restricted Investments of $7.70 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2023-02-09
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for the quarter ending 2021-12-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for the quarter ending 2020-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for the quarter ending 2019-12-31 was $14.20M.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for fiscal 2022 was $7.70M, a 67.39% increase from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for fiscal 2021 was $4.60M.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC payments to acquire restricted investments for fiscal 2019 was $68.90M.
| Period end | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 6 month as first filed | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 9 month as first filed | Payments to Acquire Restricted Investments 12 month | Payments to Acquire Restricted Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $7.70M 10-K · filed 2023-02-09 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.60M 10-K · filed 2023-02-09 | |||||
| 2021-09-30 | $4.60M 10-Q · filed 2021-11-01 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-09 | $0.00 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 10-Q · filed 2021-11-01 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-03 | ||||||
| 2019-12-31 | $14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $14.20M derived: sum of 2 quarters · filed 2022-02-11 | $14.20M derived: sum of 3 quarters · filed 2022-02-11 | $68.90M 10-K · filed 2022-02-11 | $68.86M 10-K · filed 2020-02-07 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $54.70M 10-Q · filed 2020-11-09 | $54.72M 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $54.70M 10-Q · filed 2020-08-03 | $54.72M 10-Q · filed 2019-07-29 | ||||
| 2019-03-31 | $54.70M 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |